Talvey (talquetamab)

pCPA File Number: 22937
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on or after the last therapy.
Sponsor/Manufacturer:
Janssen Inc.
CDA-AMC Project Number:
PC0363-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable